Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

6262 ARTÍCULOS , VIENDO DEL 3316 AL 3330

The prospective role of mesenchymal stem cells in Parkinson's disease

Tambe P, Undale V, Sanap A, Bhonde R, Mante N.

Parkinsonism Relat Disord. 2024 Oct;127:107087. doi: 10.1016/j.parkreldis.2024.107087. Epub 2024 Aug 10.

Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson's disease

Zhang X, Wu H, Tang B, Guo J.

Transl Neurodegener. 2024 Sep 12;13(1):48. doi: 10.1186/s40035-024-00437-6.

β-Synuclein Intermediates α-Synuclein Neurotoxicity in Parkinson's Disease

Xian M, Li J, Liu T, Hou K, Sun L, Wei J.

ACS Chem Neurosci. 2024 Jul 3;15(13):2445-2453. doi: 10.1021/acschemneuro.4c00263. Epub 2024 Jun 21.

Functional Movement Disorder as a Prodromal Symptom of Parkinson's Disease-Clinical and Pathophysiological Insights

Matar E, Tinazzi M, Edwards MJ, Bhatia KP.

Mov Disord. 2024 Nov;39(11):1952-1959. doi: 10.1002/mds.29958. Epub 2024 Aug 9.

Clinicians' viewpoints on current paradigms of care and research in Parkinson's disease

Müller T, Buhmann C, Delf M, Klostermann F, Kupsch A, Lipp A, Müngersdorf M, von Pannwitz W, Südmeyer M.

J Neural Transm (Vienna). 2024 Dec;131(12):1455-1462. doi: 10.1007/s00702-024-02822-x. Epub 2024 Aug 19.

Insights into neuroinflammatory mechanisms of deep brain stimulation in Parkinson's disease

Eser P, Kocabicak E, Bekar A, Temel Y.

Exp Neurol. 2024 Apr;374:114684. doi: 10.1016/j.expneurol.2024.114684. Epub 2024 Jan 8.

Loss of monomeric alpha-synuclein (synucleinopenia) and the origin of Parkinson's disease

Espay AJ, Lees AJ.

Parkinsonism Relat Disord. 2024 May;122:106077. doi: 10.1016/j.parkreldis.2024.106077. Epub 2024 Mar 3.

Human midbrain organoids: a powerful tool for advanced Parkinson's disease modeling and therapy exploration

Cui X, Li X, Zheng H, Su Y, Zhang S, Li M, Hao X, Zhang S, Hu Z, Xia Z, Shi C, Xu Y, Mao C.

NPJ Parkinsons Dis. 2024 Oct 20;10(1):189. doi: 10.1038/s41531-024-00799-8.

Resistance to high-fat diet-induced weight gain in transgenic mice overexpressing human wild-type α-synuclein: A model for metabolic dysfunction in Parkinson's disease

Biju KC, Hernandez ET, Stallings AM, Felix-Ortiz AC, Hebbale SK, Norton L, Mader MJ, Clark RA.

Res Sq [Preprint]. 2024 Aug 30:rs.3.rs-4870881. doi: 10.21203/rs.3.rs-4870881/v1.

Clinical Benefits of Therapeutic Interventions Targeting Mitochondria in Parkinson's Disease Patients

Ciocca M, Pizzamiglio C.

CNS Neurol Disord Drug Targets. 2024;23(5):554-561. doi: 10.2174/1871527322666230330122444.

The Role of Astrocytes and Alpha-Synuclein in Parkinson's Disease: A Review

Brash-Arias D, García LI, Pérez-Estudillo CA, Rojas-Durán F, Aranda-Abreu GE, Herrera-Covarrubias D, Chi-Castañeda D.

NeuroSci. 2024 Mar 8;5(1):71-86. doi: 10.3390/neurosci5010005. eCollection 2024 Mar.

Lactoferrin/lactoferrin receptor: Neurodegenerative or neuroprotective in Parkinson's disease?

Qian ZM, Li W, Guo Q.

Ageing Res Rev. 2024 Nov;101:102474. doi: 10.1016/j.arr.2024.102474. Epub 2024 Aug 27.

Neuronal dysfunction and gene modulation by non-coding RNA in Parkinson's disease and synucleinopathies

Meccariello R, Bellenchi GC, Pulcrano S, D'Addario SL, Tafuri D, Mercuri NB, Guatteo E.

Front Cell Neurosci. 2024 Jan 5;17:1328269. doi: 10.3389/fncel.2023.1328269. eCollection 2023.

Elimination of STN stimulation-induced dyskinesias with VIM-DBS

Shah-Zamora D, Karl J, Pearce J 3rd, Verhagen Metman L.

Mov Disord Clin Pract. 2024 Aug;11(8):1049-1052. doi: 10.1002/mdc3.14123. Epub 2024 May 31.

Allergic contact dermatitis to sodium metabisulphite in a rotigotine transdermal therapeutic system

Antunes-Duarte S, Sun L, Sousa D, Alpalhão M.

Contact Dermatitis. 2024 Dec;91(6):528-529. doi: 10.1111/cod.14676. Epub 2024 Aug 19.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias